SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Conatus Pharmaceuticals Inc. – CNAT
Pomerantz LLP is investigating claims on behalf of investors of Conatus Pharmaceuticals Inc. (“Conatus” or the “Company”) (CNAT). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Conatus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On March 5, 2015, the Company abruptly announced in a Securities and Exchange Commission filing that, “on March 2, 2015, Gary C. Burgess, M.B., Ch.B. M.Med., tendered his resignation as Senior Vice President, Clinical Research and Chief Medical Officer of Conatus Pharmaceuticals Inc., effective April 2, 2015.”
On this news, shares of Conatus fell $0.58 per share to $6.01, or more than 8.80%, on March 6, 2015.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-conatus-pharmaceuticals-inc–cnat-300046850.html